About Ardelyx (NASDAQ:ARDX)
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700
Debt
Debt-to-Equity RatioN/A
Current Ratio8.38%
Quick Ratio8.38%
Price-To-Earnings
Trailing P/E Ratio-3.57
Forward P/E Ratio-2.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$42 million
Price / Sales5.50
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book1.66
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-44.48%
Return on Assets-39.42%
Miscellaneous
Employees75
Outstanding Shares47,600,000
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx (NASDAQ:ARDX) posted its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.60. The biopharmaceutical company had revenue of $42 million for the quarter, compared to analysts' expectations of $6 million. View Ardelyx's Earnings History.
What price target have analysts set for ARDX?
6 Wall Street analysts have issued 1-year price targets for Ardelyx's stock. Their predictions range from $12.00 to $17.00. On average, they expect Ardelyx's share price to reach $13.6667 in the next year. View Analyst Ratings for Ardelyx.
What are Wall Street analysts saying about Ardelyx stock?
Here are some recent quotes from research analysts about Ardelyx stock:
- 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (3/20/2018)
- 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), ARMO BioSciences (ARMO), Urogen Pharma (URGN), Vectura Group (VEGPF), OptiNose (OPTN), Deciphera Pharmaceuticals (DCPH), Adamas Pharmaceuticals (ADMS), Vanda Pharmaceuticals (VNDA), GlycoMimetics (GLYC), NuCana (NCNA) and CymaBay Therapeutics (CBAY).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
- Dr. Reginald Seeto, COO & Exec. VP (Age 46)
- Dr. Paul Korner, Chief Medical Officer & Exec. VP (Age 52)
- Mr. Mark E. Kaufmann MBA, CFO & Treasurer (Age 50)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)
Has Ardelyx been receiving favorable news coverage?
Media headlines about ARDX stock have trended positive this week, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ardelyx earned a media sentiment score of 0.42 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 43.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $4.85.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $221.36 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ardelyx (NASDAQ:ARDX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Ardelyx in the last 12 months. Their average twelve-month price target is $13.6667, suggesting that the stock has a possible upside of 181.79%. The high price target for ARDX is $17.00 and the low price target for ARDX is $12.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.6667 | $13.6667 | $13.6667 | $16.40 |
| Price Target Upside: | 181.79% upside | 155.45% upside | 91.14% upside | 156.25% upside |
Ardelyx (NASDAQ:ARDX) Consensus Price Target History
Ardelyx (NASDAQ:ARDX) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Ardelyx (NASDAQ:ARDX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ardelyx (NASDAQ ARDX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.47%
Institutional Ownership Percentage: 74.24%
Ardelyx (NASDAQ ARDX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/24/2017 | Reginald Seeto | COO | Sell | 10,008 | $5.20 | $52,041.60 | |  |
| 8/30/2017 | Forest Baskett | Major Shareholder | Sell | 485 | $4.95 | $2,400.75 | | |
| 4/18/2017 | David P. Rosenbaum | Insider | Sell | 2,051 | $11.98 | $24,570.98 | | |
| 3/3/2017 | Jeremy S. Caldwell | EVP | Sell | 1,026 | $14.14 | $14,507.64 | | |
| 12/16/2016 | David P Rosenbaum | SVP | Sell | 900 | $14.48 | $13,032.00 | 22,144 | |
| 10/11/2016 | Jeffrey W. Jacobs | SVP | Sell | 6,000 | $15.00 | $90,000.00 | | |
| 9/23/2016 | Elizabeth A Grammer | SVP | Sell | 5,000 | $12.00 | $60,000.00 | 1,440 | |
| 9/19/2016 | Elizabeth A. Grammer | SVP | Sell | 6,859 | $11.21 | $76,889.39 | | |
| 7/18/2016 | Nea 15 Gp, Llc | Major Shareholder | Buy | 1,527,301 | $8.73 | $13,333,337.73 | | |
| 3/21/2016 | Gordon Ringold | Director | Buy | 15,000 | $7.77 | $116,550.00 | | |
| 1/13/2016 | Nea 15 Gp, Llc | Major Shareholder | Buy | 1,000,000 | $10.00 | $10,000,000.00 | | |
| 11/27/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $20.00 | $40,000.00 | 47,420 | |
| 10/8/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $19.88 | $39,760.00 | 47,420 | |
| 9/22/2015 | David P. Rosenbaum | SVP | Sell | 1,400 | $22.05 | $30,870.00 | 25,880 | |
| 9/15/2015 | David P Rosenbaum | SVP | Sell | 2,540 | $22.01 | $55,905.40 | 25,880 | |
| 9/10/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $20.59 | $41,180.00 | 47,420 | |
| 9/8/2015 | Michael Raab | CEO | Sell | 9,785 | $20.29 | $198,537.65 | 1,518 | |
| 9/3/2015 | David P Rosenbaum | SVP | Sell | 2,537 | $18.78 | $47,644.86 | 25,880 | |
| 7/22/2015 | Elizabeth A Grammer | VP | Sell | 2,500 | $18.00 | $45,000.00 | | |
| 7/15/2015 | Elizabeth A Grammer | VP | Sell | 10,000 | $17.12 | $171,200.00 | | |
| 6/10/2015 | Gordon Ringold | Director | Buy | 10,000 | $15.19 | $151,900.00 | | |
| 6/5/2015 | Enterprise Associates 12 New | Major Shareholder | Buy | 1,869,159 | $10.70 | $20,000,001.30 | | |
| 6/5/2015 | Peter G Schultz | Director | Buy | 46,729 | $10.70 | $500,000.30 | | |
| 5/4/2015 | Mark Kaufmann | CFO | Sell | 9,083 | $10.81 | $98,187.23 | | |
| 4/6/2015 | Mark Kaufmann | CFO | Sell | 7,681 | $12.80 | $98,316.80 | | |
| 3/2/2015 | Elizabeth A Grammer | VP | Sell | 1,737 | $15.81 | $27,461.97 | | |
| 2/4/2015 | Jeffrey W Jacobs | VP | Sell | 8,888 | $16.28 | $144,696.64 | | |
| 1/8/2015 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 300,000 | $24.25 | $7,275,000.00 | | |
| 12/26/2014 | Scott D Sandell | Major Shareholder | Sell | 1,972 | $21.28 | $41,964.16 | | |
| 6/24/2014 | Ventures Vii Lp Cmea | Major Shareholder | Buy | 316,826 | $14.00 | $4,435,564.00 | | |
(Data available from 1/1/2013 forward)
Ardelyx (NASDAQ ARDX) News Headlines
| Source: |
|
Ardelyx (NASDAQ:ARDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ardelyx (NASDAQ:ARDX) Income Statement, Balance Sheet and Cash Flow Statement
Ardelyx (NASDAQ ARDX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
